Is Immunomodulatory Property of Hydroxychloroquine Beneficial for Severe COVID-19? A Hospital Based Retrospective Observational Study

Mahesh Prasad Mohanta, Debabrata Behera, Deben Das, Prasant Kumar Mishra, Siddhartha Satapathy, Lavina Patnaik, Saroj Badapanda, Gayathri Prakash

Abstract


Since the beginning of the COVID-19 pandemic, Hydroxychloroquine is being prescribed by the doctors all over the world for the treatment as well as prevention of COVID-19 with varying results. As we know damage in severe COVID-19 disease occurs mainly via the immunological mechanism. There is an assumption that HCQ has immunomodulatory property and thus may have a beneficial role in severe COVID-19 disease. In this retrospective study, we describe our experience of using low dose of HCQ (200mg/day) in 27 hospitalized severe cases of COVID-19 disease. We found, though the use of HCQ resulted in improvements in chest X-rays, there was no significant reduction in the deaths in the cases where HCQ was used.

Keywords


Hydroxychloroquine, HCQ, COVID-19, SARS-Cov-2

Full Text:

PDF

References


Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst M Van: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004, 323:264-8. doi:10.1016/j.bbrc.2004.08.085

Nina PB, Dash AP: Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Indian J Public Health. 2020, 64:125-127. doi:10.4103/ijph.IJPH_496_20

Thomson K, Nachlis H. : Emergency use authorizations during the COVID-19 pandemic: lessons from hydroxychloroquine for vaccine authorization and approval. JAMA. 2020, 324:1282-1283. doi:10.1001/jama.2020.16253

Chen J, Liu D, Liu L, et al.: A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ . 2020, 49:215-219. 10.3785/j.issn. doi:1008-9292.2020.03.03

Geleris J, Sun Y, Platt J, et al.: Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020, 382:2411-8. 10. doi:1056/NEJMoa2012410

Gautret P, Lagier JC, Parola P, et al.: Hydroxychloroquine and azithromycin as a treatment of COVID 19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 , 56:105949. doi:10.1016%2Fj.ijantimicag.2020.105949

WHO: “Solidarity” clinical trial for COVID 19 treatments. (2020). Accessed: January 22, 2021: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solida

University of Oxford: The RECOVERY Trial. (2020). Accessed: November 1, 2020: https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf

Catteau L, Dauby N, Montourcy M, et al.: Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with Covid- 19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents. 2020 , 56:106144. doi:10.1016/j.ijantimicag.2020.106144

Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ: Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020, 2:689-97. doi:10.1016/S2665-9913(20)30305-2

Bénézit F, Le Bot A, Jouneau S, et al.: COVID-19 in Patient with Sarcoidosis receiving long term hydroxychloroquine treatment, France, 2020. Emerg Infect Dis. 2020 , 26:2513-2515. doi:10.3201/eid2610.201816

Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, Shi Y & Sun E: Is hydroxychloroquine beneficial for COVID-19 patients?. Cell Death Dis . 2020, 11:512. doi:10.1038/s41419-020-2721-8

Chandler L C, Yusuf IH, McClements M E, Barnard AR, MacLaren RE and Xue K: Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy. Int. J. Mol. Sci. 2020, 21(14):4972. doi:10.3390/ijms21144972

Government of India, Ministry of Health and Family Welfare: CLINICAL MANAGEMENT PROTOCOL: COVID-19. (2020). Accessed November11,2020: https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf

Pavelka K, Sen KP, Pelísková Z, et al Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens.Annals of the Rheumatic Diseases 1989;48:542-546. doi:10.1136/ard.48.7.542

Warren MA, Zhao Z, Koyama T, et al.: Severity scoring of lung edema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax. 2018 , 73:840-846. doi:10.1136/thoraxjnl-2017-211280

Gevers S, Kwa M.S.G. Kwa, Wijnans E., Nieuwkoop C Van: Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19. Clin. Microbiol. Infect.. 2020, 26:1276-1277. doi:10.1016/j.cmi.2020.05.006.

MEDCALC: Statistical Software. (2019). Accessed: December 29, 2020: https://www.medcalc.org/

Monforte A , Tavelli A, Bai F, Marchett G: Effectiveness of hydroxychloroquine in Covid-19 disease: a done and dusted deal?. Int J Infect Dis. 2020, 99:75-76. doi:10.1016/j.ijid.2020.07.056

Derwand R, Scholz M, Zelenko V: COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study. Int J Antimicrob Agents . 2020, 56:106214. doi:10.1016/j.ijantimicag.2020.106214

Parasher A: COVID- 19: Current understanding of its pathophysiology, clinical presentation, and treatment. Postgrad Med J. 2020, Published Online First:September 25. doi: 10.1136/postgradmedj-2020-138577

Richard SA , Kampo S, Hechavarria ME, Sackey M, Buunaaim ADB, Kuugbee ED, and Anabah TW: Elucidating the pivotal immunomodulatory and anti-Inflammatory potentials of chloroquine and hydroxychloroquine. J Immunol Res. 2020, 2020:4582612. doi:10.1155/2020/4582612

Roldan EQ, Biasiotto G, Magroa P, Zanella I: The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID- 19): a role for iron homeostasis?. Pharmacol Res. 2020, 158:104904. doi:10.1016/j.phrs.2020.104904

Pathak SK, Salunke AA, Thivari P, et al.: No benefit of hydroxychloroquine in COVID- 19: results of systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2020, 14:1673-1680.doi:/10.1016/j.dsx.2020.08.033

Ferner RE, Jeffrey K JK: Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 , 369:m1432. doi:10.1136/bmj.m1432

Schluger NW: The Saga of hydroxychloroquine and Covid-19: a cautionary tale. Ann Intern Med. 2020, 173:662-663. doi:10.7326/M20-5041




DOI: http://dx.doi.org/10.7575/aiac.abcmed.v.9n.2p.27

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2022 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine